More than 5 Million Americans live with them Alzheimer’s diseaseA number that will only increase as more adults reach their 60s. It is important to make strides in understanding the disease.
According to the Alzheimer’s Association, an American adult develops Alzheimer’s disease approximately every 68 seconds. But, the only way to tell the difference between Alzheimer’s and other types of dementia is after death.
Although President Obama’s brain mapping initiative is overdue it’s essential to give Alzheimer’s research and brain research the boost they need to see tangible results. Promising diagnostic tools are already in place.
“The key next step in the fight to cure Alzheimer’s is proper diagnosis,”Gerald E. Commissiong, president & CEO of Amarantus BioScience Holdings, Inc., OTCQB: AMBS, a biotech company that specializes on the diagnosis and treatment of neurodegenerative disorders like Alzheimer’s, says.
“LymPro was developed to diagnose the disorder before the disease shows any symptoms,”Commissiong. “It identifies specific biomarkers in the blood, which gives doctors the ability to definitively discern Alzheimer’s from other causes of memory loss or dementia.”
Scientists and doctors can use a diagnostic blood test to gain a better understanding of the treatment options for Alzheimer’s. The existing technology allows experts to monitor brain activity within large groups of cells. However, the new BRAIN Initiative demands an unprecedented level of neurological detail.
If Congress approves this funding, which is less than a fifth NASA’s annual sun research budget, scientists will be able to study minute cell interactions and map individual brain cells’ activity.
This combination of better treatment plans and care could be possible thanks to this knowledge. Amarantus technology’s medical benefits aren’t limited to Alzheimer’s, just as brain mapping is possible.
The publicly traded “brain company”Other neurological disorders, such as Parkinson’s disease, traumatic brain injuries and stroke, are also being addressed. LymPro is currently funded by two rounds NIH funding. Learn more about Amarantus BioScience Holdings therapeutic MANF programme. www.Amarantus.com.
